Solvent-Free Synthesis of Amide: A Novel Technique of Green Chemistry

Gohil, Chiragkumar J.; Noolvi, Malleshappa N.

doi:10.22159/ajpcr.2021.v14i5.40688

Cited by 5 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, mutant p53 cannot be targeted and impacted by this method. [15] In 2004, Vassilev and co-workers at Roche Pharmaceutical revealed "Nutlin," the first powerful MDM2 inhibitor that reactivates p53 by inhibiting MDM2. [16,17] Nutlin is an analog of cis-imidazoline with an IC 50 value between 100 and 300 nM12.…”

Section: Mdm2 Inhibitorsmentioning

confidence: 99%

Untitled

2023

IJPBA

View full text Add to dashboard Cite

Cancer is arise by inhibition of cell killing apoptosis process. Specific protein-protein interaction is responsible for the inhibition of apoptosis in the body. In this study, novel heterocyclic compounds (1,3,4-thiadiazole based) were synthesized. Synthesized compounds were successfully characterized by physical and spectral methods. And biological activity of the synthesized compounds was evaluated by cell-based assays. MTT assay was performed to determine the anti-neoplastic activity of the synthesized compounds. Moreover, a potency of the synthesized compounds was derived by IC 50 value. In an assay (in vitro), the synthesized compound induced the apoptosis in the cancer cell line. Hence, it will be proven as a potential anticancer agent.

show abstract

Section: Mdm2 Inhibitorsmentioning

confidence: 99%

Untitled

2023

IJPBA

View full text Add to dashboard Cite

show abstract

“…Previous ATS, CDC and IDSA guidelines approved treatment with a standard four-drug regimen (isoniazid, rifampin, pyrazinamide, and ethambutol) for 6 months, with isoniazid treatment discontinued after DST results became known and if isoniazid resistance was detected. 15 The addition of a fluoroquinolone to this regimen significantly increased treatment success compared to rifampin, ethambutol, and pyazinamide administered daily for 6 months (with or without isoniazid). When evaluating the effect of shortening the duration of pyazinamide administration (ranging from 1-3 months) in regimen containing fluoroquinolones, the treatment success rate was very high, with 117 of 118 patients successfully treated.…”

Section: Treatment Of Isoniazid Resistant Tbmentioning

confidence: 99%

Mechanism and management of antibiotic drug resistance tuberculosis

Gohil

Parmar²,

Patel³

et al. 2022

IJPCA

View full text Add to dashboard Cite

Drug resistance in tuberculosis has been shown to result from spontaneous mutation in several chromosomal genes of M.Tuberculosis. Mutation may reduce the medications' capacity to bind to the target genes. In many patients polydrug resistance, multidrug resistance, rifampicin resistance (RR) and extensive drug resistance (XDR) were seen. The diagnosis of drug-resistant TB in HIV-positive persons is more difficult and may be confused with other pulmonary or systemic infections. Management of patients with mono- or poly-resistant TB will be done with standard first line chemotherapy. Treatment of latent infection for people suffering from multidrug resistant bacilli is problematic because the only cure by isoniazid and rifampicin. In the recent cases of severe hepatotoxicity associated with preventive treatment comprising either pyrazinamide and rifampicin or pyrazinamide and fluoroquinolone. The use of dilatory fluoroquinolones, such as moxifloxacin, remarkable improved treatment outcomes of XDR-TB.

show abstract

“…With contrast to Functional mimetics, these types of inhibitors are generally more extended. 17 Hamilton and co-workers discovered the first compound of this class (α-helix mimetics). And it was the terphenyl derivatives.…”

Section: 222mentioning

confidence: 99%

Chemical classification of MDM2 inhibitors

Gohil

Noolvi²,

Patel³

et al. 2021

IJPCA

View full text Add to dashboard Cite

MDM2 inhibitors class of anti-neoplastic drugs has been evolve after the successful discovery of the nutlins and other potent inhibitors. MDM2 inhibitors can specifically target the tumour cells in the body, by selectively reactivating the inhibited p53 function in the tumour cells.None of the compound of this class has been entered into the market till date, all are under clinical trials. Hence, various researcher classifies them according to their p53 topology mimetic property and as per their peptide type or non-peptide type.Synthetic peptide type of inhibitors can mimic the conformation of p53 helix. Whereas, small organic molecule (non-peptide) type of MDM2 inhibitors have been further subdivided as Non α-helix mimetics (small molecule inhibitors) and α-helix mimetics. In a line with synthetic inhibitors, many potent MDM2 inhibitors are derived from the natural origin (marine, fungus). Therefore, keeping in a view of all these characteristics, here we have classified them as per best of our knowledge.

show abstract

Solvent-Free Synthesis of Amide: A Novel Technique of Green Chemistry

Cited by 5 publications

References 20 publications

Untitled

Untitled

Mechanism and management of antibiotic drug resistance tuberculosis

Chemical classification of MDM2 inhibitors

Contact Info

Product

Resources

About